The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Several late-stage pipeline products have the potential to address some of these unmet needs
Transformation to pure-play Innovative Medicines company nears completion
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
